Benzodiazepine use and misuse among patients in a methadone program

Kevin W Chen, Christine C Berger, Darlene P Forde, Christopher D'Adamo, Eric Weintraub, Devang Gandhi, Kevin W Chen, Christine C Berger, Darlene P Forde, Christopher D'Adamo, Eric Weintraub, Devang Gandhi

Abstract

Background: Benzodiazepines (BZD) misuse is a serious public health problem, especially among opiate-dependent patients with anxiety enrolled in methadone program because it puts patients at higher risk of life-threatening multiple drug overdoses. Both elevated anxiety and BZD misuse increase the risk for ex-addicts to relapse. However, there is no recent study to assess how serious the problem is and what factors are associated with BZD misuse. This study estimates the prevalence of BZD misuse in a methadone program, and provides information on the characteristics of BZD users compared to non-users.

Methods: An anonymous survey was carried out at a methadone program in Baltimore, MD, and all patients were invited to participate through group meetings and fliers around the clinic on a voluntary basis. Of the 205 returned questionnaires, 194 were complete and entered into final data analysis. Those who completed the questionnaire were offered a $5 gift card as an appreciation.

Results: 47% of the respondents had a history of BZD use, and 39.8% used BZD without a prescription. Half of the BZD users (54%) started using BZD after entering the methadone program, and 61% of previous BZD users reported increased or resumed use after entering methadone program. Compared to the non-users, BZD users were more likely to be White, have prescribed medication for mental problems, have preexistent anxiety problems before opiate use, and had anxiety problems before entering methadone program. They reported more mental health problems in the past month, and had higher scores in anxiety state, depression and perceived stress (p < .05).

Conclusions: Important information on epidemiology of BZD misuse among methadone-maintenance patients suggests that most methadone programs do not address co-occurring anxiety problems, and methadone treatment may trigger onset or worsening of BZD misuse. Further study is needed to explore how to curb misuse and abuse of BZD in the addiction population, and provide effective treatments targeting simultaneously addiction symptoms, anxiety disorders and BZD misuse.

References

    1. Ashton H. The diagnosis and management of benzodiazepine dependence. Current opinion in Psychiatry. 2005;18(3):249. doi: 10.1097/01.yco.0000165594.60434.84.
    1. Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. The American Journal on Addictions. 2001;10(1):48–68. doi: 10.1080/105504901750160484.
    1. Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J. 2007;100(3):393.
    1. Meiler A, Mino A, Chatton A, Broers B. Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician's dilemma. Schweizer Archiv für Neurologie und Psychiatrie. 2005;156(6):310–317.
    1. Peles E, Schreiber S, Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2010;107(2-3):141–148. doi: 10.1016/j.drugalcdep.2009.09.013.
    1. Lavie E, Fatséas M, Denis C, Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend. 2009;99(1-3):338–344. doi: 10.1016/j.drugalcdep.2008.07.017.
    1. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. Eur Neuropsychopharmacol. 2004;65(5):7–12.
    1. Uzun S, Kozumplik O, Jakovljević M, Sedić B. Side effects of treatment with benzodiazepines. Psychiatria Danubina. 2010;22(1):90–93.
    1. Khong E, Sim MG, Hulse G. Benzodiazepine dependence. Aust Fam Physician. 2004;33:923–926.
    1. Darke S, Ross J, Mills K, Teesson M, Williamson A, Havard A. Benzodiazepine use among heroin users: Baseline use, current use and clinical outcome. Drug Alcohol Rev. 2010;29(3):250–255.
    1. O Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(2):9–13.
    1. Kaplan EM, DuPont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. J Clin Psychiatry. 2005;21(6):941–950.
    1. Hertz JA, Knight JR. Prescription drug misuse: a growing national problem. Adolesc Med Clin. 2006;17(3):751–69. abstract xiii.
    1. Farnsworth MG. Benzodiazepine abuse and dependence: misconceptions and facts. J Fam Pract. 1990;31(4):393–400.
    1. Busto U, Sellers EM, Naranjo CA, Cappell HD, Sanchez‐Craig M, Simpkins J. Patterns of benzodiazepine abuse and dependence. Br J Addict. 1986;81(1):87–94. doi: 10.1111/j.1360-0443.1986.tb00299.x.
    1. Lankenau SE, Sanders B, Bloom JJ, Hathazi DS, Alarcon E, Tortu S, Clatts M. Prevalence and patterns of prescription drug misuse among young ketamine injectors. J Drug Iss. 2007;37(3):717.
    1. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids. Can Fam Physician. 2006;52:1081–1087.
    1. Browne R, Sloan D, Fahy S, Keating S, Moran C, O'Connor J. Detection of benzodiazepine abuse in opiate addicts. Ir Med J. 1998;91(1):18–19.
    1. El Rasheed AH. Alexithymia in Egyptian substance abusers. Substance Abuse. 2001;22(1):11–21.
    1. Peles E, Schreiber S, Adelson M. Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. European Neuropsychopharmacology. 2009;19(8):581–588. doi: 10.1016/j.euroneuro.2009.04.001.
    1. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2006;82(2):103–110. doi: 10.1016/j.drugalcdep.2005.08.011.
    1. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999;55(1-2):63–68. doi: 10.1016/S0376-8716(98)00175-6.
    1. Iguchi MY, Handelsman L, Bickel WK, Griffiths RR. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993;32(3):257–266. doi: 10.1016/0376-8716(93)90090-D.
    1. Spielberger CD. State-Trait Anxiety Inventory for Adults (Form Y) Redwood City, CA: Mind Garden Inc; 1983.
    1. Deacon BJ, Abramowitz JS, Woods CM, Tolin DF. The Anxiety Sensitivity Index-Revised: psychometric properties and factor structure in two nonclinical samples. Behav Res Ther. 2003;41(12):1427–1449. doi: 10.1016/S0005-7967(03)00065-2.
    1. Radloff LS. The CES-D Scale: A Self Report Depression Scale for Research in the General. Applied psychological measurement. 1977;1(3):385–401. doi: 10.1177/014662167700100306.
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385–396. doi: 10.2307/2136404.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever